Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company.
A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Relay Therapeutics Inc | Thomas Catinazzo | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 12.86 per share. | 14 May 2026 | 17,717 | 195,178 | - | 12.9 | 227,841 | Common Stock |
| Bionano Genomics Inc | Christopher J. Twomey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2026 | 9,149 | 9,149 | - | - | Stock Option (Right to Buy) | |
| Bionano Genomics Inc | David L. Barker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2026 | 9,149 | 9,149 | - | - | Stock Option (Right to Buy) | |
| Bionano Genomics Inc | Kristiina Vuori | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2026 | 9,149 | 9,149 | - | - | Stock Option (Right to Buy) | |
| Bionano Genomics Inc | Yvonne Linney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2026 | 9,149 | 9,149 | - | - | Stock Option (Right to Buy) | |
| Bionano Genomics Inc | Aleksandar Rajkovic | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2026 | 9,149 | 9,149 | - | - | Stock Option (Right to Buy) | |
| MeiraGTx Holdings PLC | Penny Renee Fleck | CHIEF DEVELOPMENT OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2026 | 100,000 | 100,000 | - | - | Restricted Share Units | |
| MeiraGTx Holdings PLC | Penny Renee Fleck | CHIEF DEVELOPMENT OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2026 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Surrozen Inc | Eric H. Bjerkholt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2026 | 5,550 | 5,550 | - | - | Director Stock Option (right to buy) | |
| Surrozen Inc | Christopher Y. Chai | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2026 | 5,550 | 5,550 | - | - | Director Stock Option (right to buy) | |
| Surrozen Inc | Anna Berkenblit | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2026 | 5,550 | 5,550 | - | - | Director Stock Option (right to buy) | |
| Surrozen Inc | David J. Woodhouse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2026 | 5,550 | 5,550 | - | - | Director Stock Option (right to buy) | |
| Surrozen Inc | Mace Rothenberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2026 | 5,550 | 5,550 | - | - | Director Stock Option (right to buy) | |
| Surrozen Inc | Mary Haak-Frendscho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2026 | 5,550 | 5,550 | - | - | Director Stock Option (right to buy) | |
| Rocket Pharmaceuticals Inc | Martin Wilson | General Counsel | Sale of securities on an exchange or to another person at price $ 3.61 per share. | 13 May 2026 | 3,361 | 678,639 (1%) | 0% | 3.6 | 12,120 | Common Stock |
| Dyne Therapeutics Inc | John G. Cox | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 18.36 per share. | 13 May 2026 | 3,311 | 370,834 | - | 18.4 | 60,790 | Common Stock |
| Rocket Pharmaceuticals Inc | Gaurav Shah | CEO | Sale of securities on an exchange or to another person at price $ 3.61 per share. | 13 May 2026 | 2,728 | 1,043,327 (1%) | 0% | 3.6 | 9,837 | Common Stock |
| Dyne Therapeutics Inc | Douglas Kerr | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.36 per share. | 13 May 2026 | 1,564 | 170,042 | - | 18.4 | 28,715 | Common Stock |
| Dyne Therapeutics Inc | Erick J. Lucera | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.36 per share. | 13 May 2026 | 1,448 | 123,925 | - | 18.4 | 26,585 | Common Stock |
| Rocket Pharmaceuticals Inc | John Militello | See Remarks | Sale of securities on an exchange or to another person at price $ 3.61 per share. | 13 May 2026 | 855 | 90,164 (0%) | 0% | 3.6 | 3,083 | Common Stock |
| ANI Pharma Inc | Meredith W. Cook | SR. VP, GENERAL COUNSEL & SEC. | Sale of securities on an exchange or to another person at price $ 78.16 per share. | 13 May 2026 | 500 | 78,390 (0%) | 0% | 78.2 | 39,080 | Common Stock |
| Dyne Therapeutics Inc | Johanna Friedl-Naderer | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 18.36 per share. | 13 May 2026 | 228 | 154,353 | - | 18.4 | 4,186 | Common Stock |
| Illumina Inc | Keith A. Meister | Director | 12 May 2026 | 255,378 | 4,084,886 (2%) | 0% | 102.8 | 26,257,966 | Common Stock | |
| Illumina Inc | Keith A. Meister | Director | 12 May 2026 | 255,378 | 24,562 | - | - | Equity Swap (right to buy) | ||
| Illumina Inc | Keith A. Meister | Director | 12 May 2026 | 255,378 | 3,829,508 (2%) | 0% | 144.7 | 36,942,981 | Common Stock | |
| Illumina Inc | Keith A. Meister | Director | Sale of securities on an exchange or to another person at price $ 145.26 per share. | 12 May 2026 | 159,623 | 3,669,885 (2%) | 0% | 145.3 | 23,186,837 | Common Stock |
| Protagonist Therapeutics Inc | Dinesh V. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 May 2026 | 75,000 | 225,000 | - | - | Stock Option (right to buy) | |
| Protagonist Therapeutics Inc | Dinesh V. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.58 per share. | 12 May 2026 | 75,000 | 598,478 (2%) | 0% | 21.6 | 1,618,500 | Common Stock |
| Protagonist Therapeutics Inc | Dinesh V. Patel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 100.12 per share. | 12 May 2026 | 75,000 | 523,478 (1%) | 0% | 100.1 | 7,509,000 | Common Stock |
| Protagonist Therapeutics Inc | Dinesh V. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 May 2026 | 75,000 | 225,000 | - | - | Stock Option (right to buy) | |
| Protagonist Therapeutics Inc | Dinesh V. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.58 per share. | 12 May 2026 | 75,000 | 598,478 (2%) | 0% | 21.6 | 1,618,500 | Common Stock |
| Protagonist Therapeutics Inc | Dinesh V. Patel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 100.12 per share. | 12 May 2026 | 75,000 | 523,478 (1%) | 0% | 100.1 | 7,509,000 | Common Stock |
| Shattuck Labs Inc | Andrew R. Neill | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 May 2026 | 64,027 | 0 | - | - | Warrants (Right to Buy) | |
| Shattuck Labs Inc | Andrew R. Neill | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 1.08 per share. | 12 May 2026 | 64,027 | 292,251 | - | 1.1 | 69,444 | Common Stock |
| Illumina Inc | Keith A. Meister | Director | Sale of securities on an exchange or to another person at price $ 145.94 per share. | 12 May 2026 | 53,610 | 3,616,275 (2%) | 0% | 145.9 | 7,823,843 | Common Stock |
| Illumina Inc | Keith A. Meister | Director | Sale of securities on an exchange or to another person at price $ 144.80 per share. | 12 May 2026 | 52,776 | 3,539,356 (2%) | 0% | 144.8 | 7,641,965 | Common Stock |
| Shattuck Labs Inc | Arundathy Nirmalini Pandite | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 6.61 per share. | 12 May 2026 | 30,000 | 166,219 | - | 6.6 | 198,300 | Common Stock |
| Shattuck Labs Inc | Taylor H. Schreiber | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 May 2026 | 25,610 | 0 | - | - | Warrants (Right to Buy) | |
| Shattuck Labs Inc | Taylor H. Schreiber | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 1.08 per share. | 12 May 2026 | 25,610 | 122,222 | - | 1.1 | 27,777 | Common Stock |
| Illumina Inc | Keith A. Meister | Director | Sale of securities on an exchange or to another person at price $ 146.15 per share. | 12 May 2026 | 25,352 | 3,514,004 (2%) | 0% | 146.2 | 3,705,195 | Common Stock |
| BioNTech SE (ADR) | Ramon Gomez Zapata | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2026 | 18,879 | 18,879 | - | - | Option (right to buy) | |
| BioNTech SE (ADR) | Ramon Gomez Zapata | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2026 | 15,103 | 15,103 | - | - | Performance Share Unit | |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 36.64 per share. | 12 May 2026 | 14,219 | 221,025 | - | 36.6 | 520,978 | Class A Common Stock |
| Illumina Inc | Keith A. Meister | Director | Sale of securities on an exchange or to another person at price $ 146.96 per share. | 12 May 2026 | 13,776 | 3,500,228 (2%) | 0% | 147.0 | 2,024,521 | Common Stock |
| Adma Biologics Inc | Jerrold B. Grossman | Director | Purchase of securities on an exchange or from another person at price $ 8.01 per share. | 12 May 2026 | 12,500 | 513,884 (0%) | 0% | 8.0 | 100,125 | Common Stock |
| Illumina Inc | Keith A. Meister | Director | Sale of securities on an exchange or to another person at price $ 144.13 per share. | 12 May 2026 | 12,309 | 3,592,132 (2%) | 0% | 144.1 | 1,774,096 | Common Stock |
| Twist Bioscience Corp | Jan Johannessen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 May 2026 | 12,000 | 10,304 | - | - | Employee Stock Option (right to buy) | |
| Twist Bioscience Corp | Jan Johannessen | Director | Sale of securities on an exchange or to another person at price $ 56.12 per share. | 12 May 2026 | 12,000 | 17,754 (0%) | 0% | 56.1 | 673,440 | Common Stock |
| Twist Bioscience Corp | Jan Johannessen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.00 per share. | 12 May 2026 | 12,000 | 29,754 (0%) | 0% | 14 | 168,000 | Common Stock |
| BioNTech SE (ADR) | Kylie Jimenez | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2026 | 10,488 | 10,488 | - | - | Option (right to buy) | |
| BioNTech SE (ADR) | Kylie Jimenez | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2026 | 8,391 | 8,391 | - | - | Performance Share Unit | |
| Illumina Inc | Keith A. Meister | Director | Sale of securities on an exchange or to another person at price $ 147.50 per share. | 12 May 2026 | 6,524 | 3,609,751 (2%) | 0% | 147.5 | 962,290 | Common Stock |
| Illumina Inc | Keith A. Meister | Director | Sale of securities on an exchange or to another person at price $ 148.14 per share. | 12 May 2026 | 5,310 | 3,604,441 (2%) | 0% | 148.1 | 786,623 | Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 37.09 per share. | 12 May 2026 | 4,281 | 216,744 | - | 37.1 | 158,769 | Class A Common Stock |
| Arrowhead Pharma Inc | Hongbo Lu | Director | Sale of securities on an exchange or to another person at price $ 76.88 per share. | 12 May 2026 | 2,970 | 52,012 (0%) | 0% | 76.9 | 228,334 | Common Stock |
| ANI Pharma Inc | Ori Gutwerg | SVP, GENERICS | Sale of securities on an exchange or to another person at price $ 79.50 per share. | 12 May 2026 | 2,772 | 78,696 (0%) | 0% | 79.5 | 220,374 | Common Stock |
| Shattuck Labs Inc | Abhinav A. Shukla | Chief Technical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 May 2026 | 2,032 | 50,168 | - | - | Stock Option (Right to Buy) | |
| Shattuck Labs Inc | Abhinav A. Shukla | Chief Technical Officer | Sale of securities on an exchange or to another person at price $ 7.01 per share. | 12 May 2026 | 2,032 | 81,258 | - | 7.0 | 14,244 | Common Stock |
| Shattuck Labs Inc | Abhinav A. Shukla | Chief Technical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.57 per share. | 12 May 2026 | 2,032 | 83,290 | - | 3.6 | 7,254 | Common Stock |
| ANI Pharma Inc | Thomas Rowland | SVP, HEAD - ESTABLISHED BRANDS | Sale of securities on an exchange or to another person at price $ 79.21 per share. | 12 May 2026 | 459 | 38,271 (0%) | 0% | 79.2 | 36,357 | Common Stock |
| Illumina Inc | Keith A. Meister | Director | Sale of securities on an exchange or to another person at price $ 147.80 per share. | 12 May 2026 | 180 | 3,500,048 (2%) | 0% | 147.8 | 26,604 | Common Stock |
| Odyssey Therapeutics Inc | Nan Li | Director | 11 May 2026 | 16,611,626 | 0 | - | - | Series D Convertible Preferred Stock | ||
| Odyssey Therapeutics Inc | Nan Li | Director | 11 May 2026 | 1,709,543 | 2,222,405 | - | - | Common Stock | ||
| Odyssey Therapeutics Inc | Nan Li | Director | Purchase of securities on an exchange or from another person at price $ 18.00 per share. | 11 May 2026 | 1,111,111 | 3,333,516 | - | 18 | 19,999,998 | Common Stock |
| ANI Pharma Inc | Nikhil Lalwani | Director, PRESIDENT & CEO | Sale of securities on an exchange or to another person at price $ 77.57 per share. | 11 May 2026 | 55,000 | 349,889 (2%) | 0% | 77.6 | 4,266,350 | Common Stock |
| AnaptysBio Inc | Christopher M. Murphy | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2026 | 25,765 | 25,765 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2026 | 20,000 | 61,923 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2026 | 20,000 | 81,923 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.07 per share. | 11 May 2026 | 20,000 | 787,780 (0%) | 0% | 12.1 | 241,400 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.07 per share. | 11 May 2026 | 20,000 | 787,780 (0%) | 0% | 12.1 | 241,400 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 28.58 per share. | 11 May 2026 | 14,056 | 63,443 | - | 28.6 | 401,789 | Common Stock |
| Adma Biologics Inc | Jerrold B. Grossman | Director | Purchase of securities on an exchange or from another person at price $ 8.01 per share. | 11 May 2026 | 12,500 | 501,384 (0%) | 0% | 8.0 | 100,125 | Common Stock |
| AnaptysBio Inc | Owen P. Hughes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2026 | 11,250 | 11,250 | - | - | Restricted Stock Units | |
| Arvinas Inc | Andrew R. Saik | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 9.94 per share. | 11 May 2026 | 11,139 | 193,128 (0%) | 0% | 9.9 | 110,693 | Common Stock |
| Odyssey Therapeutics Inc | Shelley Chu | Director | Purchase of securities on an exchange or from another person at price $ 18.00 per share. | 11 May 2026 | 11,111 | 11,111 | - | 18 | 199,998 | Common Stock |
| Arvinas Inc | Noah Berkowitz | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 9.94 per share. | 11 May 2026 | 11,108 | 191,395 (0%) | 0% | 9.9 | 110,385 | Common Stock |
| ANI Pharma Inc | Patrick D. Walsh | Director | Sale of securities on an exchange or to another person at price $ 80.63 per share. | 11 May 2026 | 10,000 | 38,432 (0%) | 0% | 80.6 | 806,300 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2026 | 10,000 | 51,923 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.07 per share. | 11 May 2026 | 10,000 | 777,780 (0%) | 0% | 12.1 | 120,700 | Common Stock |
| Iovance Biotherapeutics Inc | Daniel Gordon Kirby | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2026 | 10,000 | 149,381 (0%) | 0% | 0 | Common Stock | |
| Iovance Biotherapeutics Inc | Daniel Gordon Kirby | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2026 | 10,000 | 70,004 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 71.37 per share. | 11 May 2026 | 9,802 | 776,480 (0%) | 0% | 71.4 | 699,569 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 64.63 per share. | 11 May 2026 | 9,725 | 778,055 (0%) | 0% | 64.6 | 628,536 | Common Stock |
| Arvinas Inc | Randy Teel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 9.94 per share. | 11 May 2026 | 9,657 | 287,218 (0%) | 0% | 9.9 | 95,965 | Common Stock |
| Arvinas Inc | Angela Cacace | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 9.94 per share. | 11 May 2026 | 9,657 | 182,966 (0%) | 0% | 9.9 | 95,965 | Common Stock |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 25.63 per share. | 11 May 2026 | 7,763 | 84,161 (0%) | 0% | 25.6 | 198,966 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 66.33 per share. | 11 May 2026 | 6,700 | 767,780 (0%) | 0% | 66.3 | 444,391 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2026 | 6,348 | 12,698 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 29.36 per share. | 11 May 2026 | 6,348 | 69,792 | - | 29.4 | 186,348 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 11 May 2026 | 6,348 | 76,140 | - | 1.1 | 6,856 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 72.15 per share. | 11 May 2026 | 5,900 | 770,580 (0%) | 0% | 72.1 | 425,673 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2026 | 4,166 | 87,501 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.25 per share. | 11 May 2026 | 4,166 | 77,499 | - | 14.3 | 59,366 | Common Stock |
| ANI Pharma Inc | Patrick D. Walsh | Director | Sale of securities on an exchange or to another person at price $ 80.75 per share. | 11 May 2026 | 3,973 | 48,432 (0%) | 0% | 80.8 | 320,820 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 69.79 per share. | 11 May 2026 | 3,950 | 768,380 (0%) | 0% | 69.8 | 275,659 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 65.46 per share. | 11 May 2026 | 3,575 | 774,480 (0%) | 0% | 65.5 | 234,012 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2026 | 3,541 | 116,876 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.20 per share. | 11 May 2026 | 3,541 | 73,333 | - | 10.2 | 36,118 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 68.88 per share. | 11 May 2026 | 3,350 | 772,330 (0%) | 0% | 68.9 | 230,748 | Common Stock |
| Kymera Therapeutics Inc | Elena H. Ridloff | Director | Sale of securities on an exchange or to another person at price $ 87.00 per share. | 11 May 2026 | 3,000 | 0 | - | 87 | 261,000 | Common Stock |
| Kymera Therapeutics Inc | Elena H. Ridloff | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 31.20 per share. | 11 May 2026 | 3,000 | 3,000 | - | 31.2 | 93,600 | Common Stock |
| Kymera Therapeutics Inc | Elena H. Ridloff | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2026 | 3,000 | 13,000 | - | - | Stock Option (Right to Buy) | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 73.12 per share. | 11 May 2026 | 2,800 | 767,780 (0%) | 0% | 73.1 | 204,739 | Common Stock |
| Iovance Biotherapeutics Inc | Daniel Gordon Kirby | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.70 per share. | 11 May 2026 | 2,435 | 146,946 (0%) | 0% | 3.7 | 9,010 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.00 per share. | 11 May 2026 | 2,171 | 71,963 | - | 16 | 34,736 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2026 | 2,171 | 19,535 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 29.71 per share. | 11 May 2026 | 2,171 | 69,792 | - | 29.7 | 64,500 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 68.10 per share. | 11 May 2026 | 2,100 | 775,680 (0%) | 0% | 68.1 | 143,014 | Common Stock |
| Janux Therapeutics Inc | Maria Dobek | Vice President, Accounting | Sale of securities on an exchange or to another person at price $ 14.17 per share. | 11 May 2026 | 2,038 | 32,270 | - | 14.2 | 28,878 | Common Stock |
| Arvinas Inc | David K. Loomis | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 9.94 per share. | 11 May 2026 | 1,919 | 40,193 (0%) | 0% | 9.9 | 19,070 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 70.29 per share. | 11 May 2026 | 1,398 | 786,282 (0%) | 0% | 70.3 | 98,261 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 70.81 per share. | 11 May 2026 | 600 | 767,780 (0%) | 0% | 70.8 | 42,487 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 67.85 per share. | 11 May 2026 | 100 | 787,680 (0%) | 0% | 67.9 | 6,785 | Common Stock |
| Shattuck Labs Inc | Stephen Stout | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.85 per share. | 10 May 2026 | 968 | 80,561 | - | 6.9 | 6,631 | Common Stock |
| IN8bio Inc | William Ho | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2026 | 154,500 | 154,500 | - | - | Employee Stock Option (right to buy) | |
| IN8bio Inc | Kate Rochlin | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2026 | 60,000 | 60,000 | - | - | Employee Stock Option (right to buy) | |
| IN8bio Inc | Patrick McCall | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2026 | 56,250 | 56,250 | - | - | Employee Stock Option (right to buy) | |
| IN8bio Inc | Lawrence Lamb | EVP and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2026 | 54,000 | 54,000 | - | - | Employee Stock Option (right to buy) | |
| IN8bio Inc | Peter C. Brandt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2026 | 22,000 | 22,000 | - | - | Stock Option (right to buy) | |
| IN8bio Inc | Emily Wang Fairbairn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2026 | 22,000 | 22,000 | - | - | Stock Option (right to buy) | |
| IN8bio Inc | Luba Greenwood | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2026 | 22,000 | 22,000 | - | - | Stock Option (right to buy) | |
| IN8bio Inc | Jeremy R. Graff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2026 | 22,000 | 22,000 | - | - | Stock Option (right to buy) | |
| Seer Inc (Class A) | Anthony R. Bazarko | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2026 | 225,000 | 225,000 | - | - | Employee Stock Option (right to buy) | |
| Seer Inc (Class A) | Anthony R. Bazarko | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2026 | 75,000 | 75,000 | - | - | Class A Common Stock | |
| MBX Biosciences Inc | Salomon Azoulay | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 May 2026 | 55,000 | 194,540 | - | - | Stock option (right to buy) | |
| MBX Biosciences Inc | Salomon Azoulay | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 38.38 per share. | 08 May 2026 | 55,000 | 14,769 | - | 38.4 | 2,110,900 | Common Stock |
| MBX Biosciences Inc | Salomon Azoulay | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.46 per share. | 08 May 2026 | 55,000 | 69,769 | - | 10.5 | 575,300 | Common Stock |
| Spyre Therapeutics Inc | Michael Henderson | Director | Sale of securities on an exchange or to another person at price $ 73.72 per share. | 08 May 2026 | 33,513 | 132,689 (0%) | 0% | 73.7 | 2,470,578 | Common Stock |
| uniQure NV | Walid Abi-Saab | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.59 per share. | 08 May 2026 | 25,000 | 214,669 (0%) | 0% | 5.6 | 139,750 | Ordinary Shares |
| uniQure NV | Walid Abi-Saab | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 May 2026 | 25,000 | 60,500 | - | - | Stock Option (Right to Buy) | |
| uniQure NV | Walid Abi-Saab | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 25.10 per share. | 08 May 2026 | 25,000 | 189,669 (0%) | 0% | 25.1 | 627,500 | Ordinary Shares |
| Spyre Therapeutics Inc | Michael Henderson | Director | Sale of securities on an exchange or to another person at price $ 74.76 per share. | 08 May 2026 | 24,814 | 107,875 (0%) | 0% | 74.8 | 1,855,095 | Common Stock |
| uniQure NV | Walid Abi-Saab | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 08 May 2026 | 20,000 | 169,669 (0%) | 0% | 25 | 500,000 | Ordinary Shares |
| Spyre Therapeutics Inc | Michael Henderson | Director | Sale of securities on an exchange or to another person at price $ 75.35 per share. | 08 May 2026 | 19,269 | 88,606 (0%) | 0% | 75.3 | 1,451,919 | Common Stock |
| MBX Biosciences Inc | Salomon Azoulay | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 May 2026 | 15,003 | 30,008 | - | - | Stock option (right to buy) | |
| MBX Biosciences Inc | Salomon Azoulay | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 38.30 per share. | 08 May 2026 | 15,003 | 14,769 | - | 38.3 | 574,615 | Common Stock |
| MBX Biosciences Inc | Salomon Azoulay | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.00 per share. | 08 May 2026 | 15,003 | 29,772 | - | 16 | 240,048 | Common Stock |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 08 May 2026 | 10,000 | 134,985 (0%) | 0% | 30 | 300,000 | Ordinary Shares |
| Bio-Techne | Amy Herr | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 May 2026 | 6,636 | 0 | - | - | Stock Option (Right to Buy) | |
| Bio-Techne | Amy Herr | Director | Sale of securities on an exchange or to another person at price $ 48.28 per share. | 08 May 2026 | 6,636 | 200 (0%) | 0% | 48.3 | 320,386 | Common Stock |
| Bio-Techne | Amy Herr | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.60 per share. | 08 May 2026 | 6,636 | 6,836 (0%) | 0% | 47.6 | 315,874 | Common Stock |
| Twist Bioscience Corp | Robert F. Werner | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 56.88 per share. | 08 May 2026 | 4,961 | 49,674 (0%) | 0% | 56.9 | 282,187 | Common Stock |
| Spyre Therapeutics Inc | Michael Henderson | Director | Sale of securities on an exchange or to another person at price $ 72.57 per share. | 08 May 2026 | 2,404 | 166,202 (0%) | 0% | 72.6 | 174,458 | Common Stock |
| Odyssey Therapeutics Inc | Jason Haas | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 20.00 per share. | 08 May 2026 | 1,000 | 62,908 | - | 20 | 20,000 | Common Stock |
| Odyssey Therapeutics Inc | Gary D. Glick | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2026 | 884,450 | 884,450 | - | - | Stock Option (Right to Buy) | |
| Odyssey Therapeutics Inc | Jeffrey M Leiden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2026 | 626,220 | 626,220 | - | - | Stock Option (Right to Buy) | |
| Odyssey Therapeutics Inc | Anthony Opipari | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2026 | 250,203 | 250,203 | - | - | Stock Option (Right to Buy) | |
| Sionna Therapeutics Inc | Peter A. Thompson | Director | Sale of securities on an exchange or to another person at price $ 46.22 per share. | 07 May 2026 | 184,639 | 2,671,822 | - | 46.2 | 8,534,015 | Common Stock |
| Odyssey Therapeutics Inc | Gary D. Glick | Director, See Remarks | 07 May 2026 | 166,116 | 0 | - | - | Series D Convertible Preferred Stock | ||
| Odyssey Therapeutics Inc | Jeffrey M Leiden | Director | 07 May 2026 | 100,000 | 0 | - | - | Series C Convertible Preferred Stock | ||
| Odyssey Therapeutics Inc | Gary D. Glick | Director, See Remarks | 07 May 2026 | 100,000 | 0 | - | - | Series C Convertible Preferred Stock | ||
| Odyssey Therapeutics Inc | Jeffrey M Leiden | Director | 07 May 2026 | 96,002 | 0 | - | - | Series D Convertible Preferred Stock | ||
| Odyssey Therapeutics Inc | Collin Todd | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2026 | 93,904 | 93,904 | - | - | Stock Option (Right to Buy) | |
| Odyssey Therapeutics Inc | Natalie Dales | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2026 | 79,773 | 79,773 | - | - | Stock Option (Right to Buy) | |
| Illumina Inc | Keith A. Meister | Director | 07 May 2026 | 79,568 | 279,940 | - | - | Equity Swap (right to buy) | ||
| Illumina Inc | Keith A. Meister | Director | 07 May 2026 | 79,568 | 3,829,508 (2%) | 0% | 143.5 | 11,414,030 | Common Stock | |
| Illumina Inc | Keith A. Meister | Director | 07 May 2026 | 79,568 | 3,909,076 (2%) | 0% | 102.8 | 8,181,182 | Common Stock | |
| Odyssey Therapeutics Inc | Jeffrey M Leiden | Director | 07 May 2026 | 79,166 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Recursion Pharma Inc (Class A) | Christopher Gibson | Director | 07 May 2026 | 60,000 | 966,556 | - | 0 | Class A Common Stock | ||
| Recursion Pharma Inc (Class A) | Christopher Gibson | Director | 07 May 2026 | 60,000 | 4,343,334 | - | - | Class B Common Stock | ||
| Sionna Therapeutics Inc | Peter A. Thompson | Director | Sale of securities on an exchange or to another person at price $ 44.58 per share. | 07 May 2026 | 59,767 | 2,856,461 | - | 44.6 | 2,664,413 | Common Stock |
| Sionna Therapeutics Inc | Peter A. Thompson | Director | Sale of securities on an exchange or to another person at price $ 44.61 per share. | 07 May 2026 | 48,546 | 2,916,228 | - | 44.6 | 2,165,637 | Common Stock |
| Recursion Pharma Inc (Class A) | Christopher Gibson | Director | Sale of securities on an exchange or to another person at price $ 3.37 per share. | 07 May 2026 | 40,000 | 926,556 | - | 3.4 | 134,800 | Class A Common Stock |
| Protagonist Therapeutics Inc | Bryan Giraudo | Director | Sale of securities on an exchange or to another person at price $ 100.14 per share. | 07 May 2026 | 36,000 | 27,825 (0%) | 0% | 100.1 | 3,605,040 | Common Stock |
| Odyssey Therapeutics Inc | Jeffrey M Leiden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2026 | 28,800 | 0 | - | - | Series D Warrants (Right to Buy) | |
| Odyssey Therapeutics Inc | Jeffrey M Leiden | Director | 07 May 2026 | 28,698 | 28,698 | - | - | Common Stock | ||
| Odyssey Therapeutics Inc | Anthony Opipari | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2026 | 27,777 | 27,777 | - | - | Stock Option (Right to Buy) | |
| Odyssey Therapeutics Inc | Ian F. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2026 | 27,393 | 27,393 | - | - | Stock Option (Right to Buy) | |
| Odyssey Therapeutics Inc | Timothy P. Walbert | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2026 | 27,393 | 27,393 | - | - | Stock Option (Right to Buy) | |
| Odyssey Therapeutics Inc | Valerie Odegard, | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2026 | 27,393 | 27,393 | - | - | Stock Option (Right to Buy) | |
| Odyssey Therapeutics Inc | Gary D. Glick | Director, See Remarks | 07 May 2026 | 27,386 | 415,973 | - | - | Common Stock | ||
| Protagonist Therapeutics Inc | Bryan Giraudo | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2026 | 24,000 | 0 | - | - | Stock Option (right to buy) | |
| Protagonist Therapeutics Inc | Bryan Giraudo | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.45 per share. | 07 May 2026 | 24,000 | 31,825 (0%) | 0% | 6.5 | 154,800 | Common Stock |
| Recursion Pharma Inc (Class A) | Christopher Gibson | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 07 May 2026 | 20,000 | 906,556 | - | 0 | Class A Common Stock | |
| Odyssey Therapeutics Inc | Anthony Opipari | See Remarks | 07 May 2026 | 20,000 | 0 | - | - | Series C Convertible Preferred Stock | ||
| Odyssey Therapeutics Inc | Anthony Opipari | See Remarks | 07 May 2026 | 18,531 | 0 | - | - | Series A Convertible Preferred Stock | ||
| Rocket Pharmaceuticals Inc | Sarbani Chaudhuri | See Remarks | Sale of securities on an exchange or to another person at price $ 3.84 per share. | 07 May 2026 | 17,650 | 267,510 (0%) | 0% | 3.8 | 67,741 | Common Stock |
| Odyssey Therapeutics Inc | Anthony Opipari | See Remarks | 07 May 2026 | 17,545 | 0 | - | - | Series D Convertible Preferred Stock | ||
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 66.65 per share. | 07 May 2026 | 13,974 | 4,364,473 (3%) | 0% | 66.7 | 931,374 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 66.65 per share. | 07 May 2026 | 13,973 | 561,713 (0%) | 0% | 66.7 | 931,307 | Common Stock |
| Protagonist Therapeutics Inc | Bryan Giraudo | Director | Sale of securities on an exchange or to another person at price $ 100.07 per share. | 07 May 2026 | 12,000 | 6,000 (0%) | 0% | 100.1 | 1,200,840 | Common Stock |
| Protagonist Therapeutics Inc | Bryan Giraudo | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.98 per share. | 07 May 2026 | 12,000 | 43,825 (0%) | 0% | 7.0 | 83,760 | Common Stock |
| Protagonist Therapeutics Inc | Bryan Giraudo | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2026 | 12,000 | 0 | - | - | Stock Option (right to buy) | |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 67.49 per share. | 07 May 2026 | 11,217 | 584,469 (0%) | 0% | 67.5 | 757,091 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 67.49 per share. | 07 May 2026 | 11,217 | 4,387,230 (3%) | 0% | 67.5 | 757,090 | Common Stock |
| Odyssey Therapeutics Inc | Anthony Opipari | See Remarks | 07 May 2026 | 11,083 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Illumina Inc | Keith A. Meister | Director | 07 May 2026 | 9,236 | 3,838,744 (2%) | 0% | 102.8 | 949,646 | Common Stock | |
| Illumina Inc | Keith A. Meister | Director | 07 May 2026 | 9,236 | 359,508 | - | - | Equity Swap (right to buy) | ||
| Illumina Inc | Keith A. Meister | Director | 07 May 2026 | 9,236 | 3,829,508 (2%) | 0% | 140.3 | 1,295,349 | Common Stock | |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 68.38 per share. | 07 May 2026 | 8,334 | 4,378,896 (3%) | 0% | 68.4 | 569,858 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 68.38 per share. | 07 May 2026 | 8,333 | 576,136 (0%) | 0% | 68.4 | 569,790 | Common Stock |
| Odyssey Therapeutics Inc | Anthony Opipari | See Remarks | 07 May 2026 | 6,965 | 6,965 | - | - | Common Stock | ||
| Protagonist Therapeutics Inc | Bryan Giraudo | Director | Sale of securities on an exchange or to another person at price $ 100.00 per share. | 07 May 2026 | 6,000 | 0 (0%) | 0% | 100 | 600,000 | Common Stock |
| Odyssey Therapeutics Inc | Anthony Opipari | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2026 | 5,263 | 0 | - | - | Series D Warrants (Right to Buy) | |
| Protagonist Therapeutics Inc | Bryan Giraudo | Director | Sale of securities on an exchange or to another person at price $ 100.00 per share. | 07 May 2026 | 5,130 | 12,695 (0%) | 0% | 100 | 513,000 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 67.35 per share. | 07 May 2026 | 5,077 | 556,636 (0%) | 0% | 67.3 | 341,913 | Common Stock |
| BridgeBio Pharma Inc | Neil Kumar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 67.35 per share. | 07 May 2026 | 5,076 | 4,359,397 (3%) | 0% | 67.3 | 341,846 | Common Stock |
| Odyssey Therapeutics Inc | Jeffrey M Leiden | Director | Purchase of securities on an exchange or from another person at price $ 20.00 per share. | 07 May 2026 | 5,000 | 270,198 | - | 20 | 100,000 | Common Stock |
| Biomarin pharma Inc - Registered Shares | Gregory R. Friberg | EVP, Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 53.85 per share. | 07 May 2026 | 3,281 | 51,818 (0%) | 0% | 53.9 | 176,682 | Common Stock |
| Odyssey Therapeutics Inc | Jeffrey M Leiden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2026 | 2,963 | 31,661 | - | - | Common Stock |
This section tracks all disclosures required by the U.S. Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934, particularly those related to Section 16 and Rule 10b-5, which govern insider trading activities in the U.S. market. These disclosures are made by corporate insiders, including executives, officers, directors, significant employees, and large shareholders, who are buying and selling stock in their own companies. You can search and filter within these results. You can also sort the information by clicking on the column headers.